advertisement

Oculus

Xu X 9

Showing records 1 to 9 | Display all abstracts from Xu X

82602 Risk factors for visual field loss progression in patients with primary open-angle glaucoma in Wenzhou area
Zhou K
Chinese Journal of Ophthalmology 2019; 55: 777-784
82844 In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery
Zhang Y
Journal of Ophthalmology 2019; 2019: 7419571
82602 Risk factors for visual field loss progression in patients with primary open-angle glaucoma in Wenzhou area
Shang X
Chinese Journal of Ophthalmology 2019; 55: 777-784
82844 In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery
Zhu S
Journal of Ophthalmology 2019; 2019: 7419571
82602 Risk factors for visual field loss progression in patients with primary open-angle glaucoma in Wenzhou area
Wang XY
Chinese Journal of Ophthalmology 2019; 55: 777-784
82844 In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery
Xu X
Journal of Ophthalmology 2019; 2019: 7419571
82602 Risk factors for visual field loss progression in patients with primary open-angle glaucoma in Wenzhou area
Wang XJ
Chinese Journal of Ophthalmology 2019; 55: 777-784
82844 In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery
Zuo L
Journal of Ophthalmology 2019; 2019: 7419571
82602 Risk factors for visual field loss progression in patients with primary open-angle glaucoma in Wenzhou area
Cheng HH; Hu HS; Huang QJ; Pan XF; Xu X; Liang YB
Chinese Journal of Ophthalmology 2019; 55: 777-784

Issue 20-4

Select Issue


advertisement

WGW-2021